Beta Bionics (BBNX) vs Tactile Systems Technology (TCMD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Tactile Systems Technology (TCMD) has outperformed Beta Bionics (BBNX) over the past year, losing 0.4% versus a loss of 57.5%. Beta Bionics is the larger company by market cap ($726.3 million vs $573.5 million), about 1.3 times the size. Tactile Systems Technology converts more of its revenue into profit, with a net margin of 5.8% versus -73.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BBNX | TCMD |
|---|---|---|
| Share price | $13.36 | $25.60 |
| Market cap | $726.34M | $573.48M |
| 1-day change | +0.30% | -1.50% |
| YTD return | -56.15% | -11.72% |
| 1-year return | -57.48% | -0.39% |
| 5-year return | — | +23.85% |
| P/E ratio (TTM) | — | 24.85 |
| Forward P/E | — | 17.41 |
| EPS (TTM) | $-1.83 | $1.03 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $100.25M | $329.52M |
| Revenue growth (YoY) | +53.94% | +12.47% |
| Net income (latest FY) | $-73.20M | $19.09M |
| Gross margin | 55.40% | 75.91% |
| Operating margin | -71.50% | 8.89% |
| Net margin | -73.02% | 5.79% |
| 52-week high | $32.71 | $37.77 |
| 52-week low | $8.80 | $20.53 |
| Distance from 52-week high | -59.16% | -32.22% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +87.87% | +41.91% |
| Average volume | 1.21M | 248.63K |
| Shares outstanding | 54.37M | 22.40M |
| Employees | 420 | 1,086 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TCMD has outperformed BBNX by 57.1 percentage points over the past year.
- Tactile Systems Technology is more profitable, keeping 5.8 cents of every revenue dollar as net income versus -73.0 cents for Beta Bionics.
- Beta Bionics grew revenue faster in its latest fiscal year (+53.94% vs +12.47%).
About Beta Bionics
BBNX stock →Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older.
Health Care · Medical/Dental Instruments · 420 employees
About Tactile Systems Technology
TCMD stock →Tactile Systems Technology, Inc., a medical technology company, develops and provides medical devices to treat underserved chronic diseases in the United States. It offers Flexitouch Plus system, a pneumatic compression device for the treatment of lymphedema, phlebolymphedema, lipedema, venous insufficiencies, and other types of edema and leg ulcers; Entre Plus System, a pneumatic compression device for the at-home treatment of lymphedema, chronic edema, venous insufficiency, and chronic wounds.
Health Care · Medical/Dental Instruments · 1,086 employees
BBNX vs TCMD FAQ
Which is bigger, Beta Bionics or Tactile Systems Technology?
Beta Bionics (BBNX) is larger, with a market capitalization of $726.34M compared with $573.48M for Tactile Systems Technology (TCMD).
Which stock has performed better over the past year, BBNX or TCMD?
TCMD returned -0.39% over the past 12 months, compared with -57.48% for BBNX (price return, excluding dividends). Past performance does not predict future results.
Are Beta Bionics and Tactile Systems Technology in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.